New combo therapy aims to wipe out rectal cancer before surgery
NCT ID NCT07381400
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding an immunotherapy drug (serplulimab) to standard chemotherapy before surgery can improve outcomes for people with a common type of locally advanced rectal cancer (MSS/pMMR). About 128 participants will be randomly assigned to receive either chemo alone or chemo plus immunotherapy for six cycles before surgery. The main goal is to see if the combination leads to a higher rate of complete cancer disappearance (pathological complete response).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mFOLFOX6 chemotherapy and serplulimab (an immunotherapy drug)
What this could lead to
If successful, this combination could increase the chance of eliminating all cancer before surgery, potentially reducing the need for more aggressive treatments.
What could go wrong
This is an early phase 2 trial with only 128 participants, so results may not apply to everyone. Immunotherapy can cause immune-related side effects, and the added benefit over chemotherapy alone is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••